Development, ChildRef MPSTNCT06448520
Reference Values for the Muscle Power Sprint Test
A study testing Muscle Power Sprint Test in people with Development, Child and Activity, Motor, run by Erasmus Medical Center at 1 site in Netherlands.
Trial summary
The goal of this prospective, cross-sectional study is to develop updated reference values for the Muscle Power Sprint Test (MPST) in children aged 5-12 years. The main question it aims to answer is: What are reference ('normal') values for the MPST in children aged 5-12 years? Participants will be asked to perform… Read more about this study
- Who is it for?
- Ages 5 to 12 yearsHealthy volunteers can take part
- Conditions the study is for
- Development, Child, Activity, Motor
- What is being tested?
- Muscle Power Sprint Test
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 480 participants
- Where
- 1 siteNetherlands
- Study dates
- 1 Dec 2024to Sep 2025
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 5 to 12 years
- All sexes
- Healthy volunteers accepted
- Child
Who may be able to join
- Age 5-12 years
- Attending primary education at one of the participating schools or attending participating after-school childcare centers.
Who cannot join
- Contra-indication for maximal exercise due to cardiac or respiratory morbidities
- Injuries limiting maximal exercise capacity
- Known with motor function impairment which may hamper maximal exercise (e.g. neurologic comorbidities)
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Netherlands1 site, 1 recruiting
- Recruiting
Erasmus MC, Sophia Children's Hospital
Rotterdam, South Holland, 3015 GD
Louis Dossche, MD, 00317036084, l.dossche@erasmusmc.nl
About this study
Official title: Reference Values for the Muscle Power Sprint Test in Children Aged 5-12 Years
The goal of this prospective, cross-sectional study is to develop updated reference values for the Muscle Power Sprint Test (MPST) in children aged 5-12 years.
The main question it aims to answer is:
- What are reference ('normal') values for the MPST in children aged 5-12 years?
Participants will be asked to perform six short sprints of fifteen meters each, with a ten-second rest between each effort.
Read the detailed description
SUMMARY Rationale: Children with congenital abnormalities face risks of below-average lung function and exercise tolerance (1-3). As the standard of care, our tertiary hospital enrolls these children in a prospective, longitudinal follow-up program from birth (4). This program involves regular assessments of overall health and development, including spirometry and exercise tolerance tests conducted by pediatric physiotherapists. Historically, the Bruce treadmill protocol was employed for testing maximal exercise tolerance in children aged 4 and above, but it presented limitations such as high muscular demands of the steep inclines and large workload increments, impacting reliability and potentially causing premature discontinuation (5).
In response, the Bruce protocol was replaced in newer follow-up program versions by the Muscle Power Sprint Test (MPST). Unlike the Bruce protocol, which assesses aerobic capacity, the MPST focuses on anaerobic exercise capacity, which is crucial for children's daily activities like playing with peers (6). Performing the MPST involves six short runs of 15 meters, from which the calculated 'mean power' serves as the primary outcome. The distance covered during these runs corresponds well to the distances children cover during daily play activities.
While Dutch norm values for children aged 6-18 exist, gathered mainly in rural areas between 2012 and 2016, the study highlights the need for updated reference values. Lifestyle changes, exacerbated by the Covid-19 pandemic, underscore the urgency of updating exercise tolerance reference values (7). Notably, there is a current lack of established reference values for 5-year-olds undergoing MPST testing in our longitudinal follow-up program, emphasizing the need for comparative data in this age group.
Objective: Our primary goal is to establish reference values for the MPST for primary school children aged 5-12 belonging to a diverse population living in the Netherlands.
Study design: The study adopts a prospective cross-sectional design.
Study population: Primary school or after-school childcare children aged 5-12 years.
Intervention (if applicable): The MPST, which involves six 15-meter sprints at maximum pace between the two cones/lines, with a 10-second rest in between each effort.
Main study parameters/endpoints: The primary outcome is generating reference values for the MPST for typical children aged 5-12.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness: We believe the risks of experiencing drawbacks from study participation are minimal. The Muscle Power Sprint Test (MPST) is non-invasive, involving six short, consecutive 15-meter sprints - similar to activities children commonly engage in, such as games like tag or hide-and-seek - with a 10-second rest after every run. Individual testing and warm-up rounds further mitigate potential risks, and we estimate the likelihood of injuries or adverse effects to be lower than those encountered in a standard physical education class.
- Conditions
- Development, Child, Activity, Motor
- Being tested
- Muscle Power Sprint Test
- Medical subject headings
- Motor Activity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Muscle Power Sprint TestOther
The Muscle Power Sprint Test (MPST) is an easy-to-perform field test of anaerobic capacity for children and adolescents. The only necessities for the administration of this test are an open space, a stopwatch and two cones or lines. Test subjects are encouraged to perform six 15-meter sprints at a maximal pace between the two cones/lines, with a 10-second rest in between each effort. The distance covered during these short runs corresponds well to the distances children cover during daily play activities. The power that is generated with each sprint can be calculated using the formula: power = (total mass x 15 m²)/time³.
| Study group | Role | What they receive |
|---|---|---|
| Muscle Power Sprint Test (MPST) | Experimental | All patients in this arm will be assessed through the MPST. We calculate the mean Power developed during the six short distance sprints, using time needed for each sprint and the weight of the study subject. Receives: Other: Muscle Power Sprint Test |
What is being measured
The primary outcome is the main question the study is designed to answer.
Reference values for the MPST for children aged 5-12 years, both male and female.
Reference values for the MPST for children aged 5-12 years, both male and female.
Measured: Data gathering: 6 months, data processing: 6 months.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Jun 2024
- Study start1 Dec 2024
- Primary completionJun 2025 (estimated)
- Study completionSep 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (7)Papers the sponsor has linked to this study.
- Other trials for Development, ChildStudies of the same condition, open and under way.
- More trials run by Erasmus Medical CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 480 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Erasmus Medical Center
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Louis Dossche, Erasmus Medical Center
- Investigators
- Marco Schnater, MD, PhD, Principal investigator, Erasmus Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06448520
- Sponsor's protocol ID
- NL86724.000.24
- Other IDs
- 12322
- Acronym
- Ref MPST
- Status last verified
- Feb 2025
- First submitted
- 4 Jun 2024
- Last updated
- 25 Feb 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: We can share the raw MPST data when requested by other researchers.
Publications
Hijkoop A, van Schoonhoven MM, van Rosmalen J, Tibboel D, van der Cammen-van Zijp MHM, Pijnenburg MW, Cohen-Overbeek TE, Schnater JM, IJsselstijn H. Lung function, exercise tolerance, and physical growth of children with congenital lung malformations at 8 years of age. Pediatr Pulmonol. 2019 Aug;54(8):1326-1334. doi: 10.1002/ppul.24345. Epub 2019 Apr 22.
PubMed 31012287Schaan CW, Macedo ACP, Sbruzzi G, Umpierre D, Schaan BD, Pellanda LC. Functional Capacity in Congenital Heart Disease: A Systematic Review and Meta-Analysis. Arq Bras Cardiol. 2017 Oct;109(4):357-367. doi: 10.5935/abc.20170125. Epub 2017 Sep 4.
PubMed 28876372Toussaint-Duyster LCC, van der Cammen-van Zijp MHM, de Jongste JC, Tibboel D, Wijnen RMH, Gischler SJ, van Rosmalen J, IJsselstijn H. Congenital diaphragmatic hernia and exercise capacity, a longitudinal evaluation. Pediatr Pulmonol. 2019 May;54(5):628-636. doi: 10.1002/ppul.24264. Epub 2019 Feb 11.
PubMed 30741484Gischler SJ, Mazer P, Duivenvoorden HJ, van Dijk M, Bax NM, Hazebroek FW, Tibboel D. Interdisciplinary structural follow-up of surgical newborns: a prospective evaluation. J Pediatr Surg. 2009 Jul;44(7):1382-9. doi: 10.1016/j.jpedsurg.2008.12.034.
PubMed 19573666Fredriksen PM, Ingjer F, Nystad W, Thaulow E. Aerobic endurance testing of children and adolescents--a comparison of two treadmill-protocols. Scand J Med Sci Sports. 1998 Aug;8(4):203-7. doi: 10.1111/j.1600-0838.1998.tb00193.x.
PubMed 9764441Bailey RC, Olson J, Pepper SL, Porszasz J, Barstow TJ, Cooper DM. The level and tempo of children's physical activities: an observational study. Med Sci Sports Exerc. 1995 Jul;27(7):1033-41. doi: 10.1249/00005768-199507000-00012.
PubMed 7564970Stockwell S, Trott M, Tully M, Shin J, Barnett Y, Butler L, McDermott D, Schuch F, Smith L. Changes in physical activity and sedentary behaviours from before to during the COVID-19 pandemic lockdown: a systematic review. BMJ Open Sport Exerc Med. 2021 Feb 1;7(1):e000960. doi: 10.1136/bmjsem-2020-000960. eCollection 2021.
PubMed 34192010
Study at a glance
From the registry record, last updated by the sponsor on 25 Feb 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Reference Values for the Muscle Power Sprint Test in Children Aged 5-12 Years
- ClinicalTrials.gov ID
- NCT06448520
- Acronym / sponsor ID
- Ref MPST / NL86724.000.24
- Conditions
- Development, Child, Activity, Motor
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 480 participants (estimated)
- Lead sponsor
- Erasmus Medical CenterUniversity, hospital or other
- Study start
- 1 Dec 2024 (actual)
- Primary completion
- Jun 2025 (estimated)
- Study completion
- Sep 2025 (estimated)
- First posted
- 7 Jun 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this prospective, cross-sectional study is to develop updated reference values for the Muscle Power Sprint Test (MPST) in children aged 5-12 years.
The main question it aims to answer is:
- What are reference ('normal') values for the MPST in children aged 5-12 years?
Participants will be asked to perform six short sprints of fifteen meters each, with a ten-second rest between each effort.
Detailed description
SUMMARY Rationale: Children with congenital abnormalities face risks of below-average lung function and exercise tolerance (1-3). As the standard of care, our tertiary hospital enrolls these children in a prospective, longitudinal follow-up program from birth (4). This program involves regular assessments of overall health and development, including spirometry and exercise tolerance tests conducted by pediatric physiotherapists. Historically, the Bruce treadmill protocol was employed for testing maximal exercise tolerance in children aged 4 and above, but it presented limitations such as high muscular demands of the steep inclines and large workload increments, impacting reliability and potentially causing premature discontinuation (5).
In response, the Bruce protocol was replaced in newer follow-up program versions by the Muscle Power Sprint Test (MPST). Unlike the Bruce protocol, which assesses aerobic capacity, the MPST focuses on anaerobic exercise capacity, which is crucial for children's daily activities like playing with peers (6). Performing the MPST involves six short runs of 15 meters, from which the calculated 'mean power' serves as the primary outcome. The distance covered during these runs corresponds well to the distances children cover during daily play activities.
While Dutch norm values for children aged 6-18 exist, gathered mainly in rural areas between 2012 and 2016, the study highlights the need for updated reference values. Lifestyle changes, exacerbated by the Covid-19 pandemic, underscore the urgency of updating exercise tolerance reference values (7). Notably, there is a current lack of established reference values for 5-year-olds undergoing MPST testing in our longitudinal follow-up program, emphasizing the need for comparative data in this age group.
Objective: Our primary goal is to establish reference values for the MPST for primary school children aged 5-12 belonging to a diverse population living in the Netherlands.
Study design: The study adopts a prospective cross-sectional design.
Study population: Primary school or after-school childcare children aged 5-12 years.
Intervention (if applicable): The MPST, which involves six 15-meter sprints at maximum pace between the two cones/lines, with a 10-second rest in between each effort.
Main study parameters/endpoints: The primary outcome is generating reference values for the MPST for typical children aged 5-12.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness: We believe the risks of experiencing drawbacks from study participation are minimal. The Muscle Power Sprint Test (MPST) is non-invasive, involving six short, consecutive 15-meter sprints - similar to activities children commonly engage in, such as games like tag or hide-and-seek - with a 10-second rest after every run. Individual testing and warm-up rounds further mitigate potential risks, and we estimate the likelihood of injuries or adverse effects to be lower than those encountered in a standard physical education class.
Study design
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Muscle Power Sprint Test (MPST) | Experimental | Other: Muscle Power Sprint TestAll patients in this arm will be assessed through the MPST. We calculate the mean Power developed during the six short distance sprints, using time needed for each sprint and the weight of the study subject. |
Who may qualify
- Ages
- 5 to 12 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child
Key inclusion criteria (2 listed)
- Age 5-12 years
- Attending primary education at one of the participating schools or attending participating after-school childcare centers.
Key exclusion criteria (3 listed)
- Contra-indication for maximal exercise due to cardiac or respiratory morbidities
- Injuries limiting maximal exercise capacity
- Known with motor function impairment which may hamper maximal exercise (e.g. neurologic comorbidities)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Muscle Power Sprint TestThe Muscle Power Sprint Test (MPST) is an easy-to-perform field test of anaerobic capacity for children and adolescents. The only necessities for the administration of this test are an open space, a stopwatch and two cones or lines. Test subjects are encouraged to perform six 15-meter sprints at a maximal pace between the two cones/lines, with a 10-second rest in between each effort. The distance covered during these short runs corresponds well to the distances children cover during daily play activities. The power that is generated with each sprint can be calculated using the formula: power = (total mass x 15 m²)/time³. | Other | Muscle Power Sprint Test (MPST) |
Primary outcome
Reference values for the MPST for children aged 5-12 years, both male and female.
Time frame: Data gathering: 6 months, data processing: 6 months.
Reference values for the MPST for children aged 5-12 years, both male and female.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Feb 2025.
- Background: PubMed 31012287Hijkoop A, van Schoonhoven MM, van Rosmalen J, Tibboel D, van der Cammen-van Zijp MHM, Pijnenburg MW, Cohen-Overbeek TE, Schnater JM, IJsselstijn H. Lung function, exercise tolerance, and physical growth of children with congenital lung malformations at 8 years of age. Pediatr Pulmonol. 2019 Aug;54(8):1326-1334. doi: 10.1002/ppul.24345. Epub 2019 Apr 22.
- Background: PubMed 28876372Schaan CW, Macedo ACP, Sbruzzi G, Umpierre D, Schaan BD, Pellanda LC. Functional Capacity in Congenital Heart Disease: A Systematic Review and Meta-Analysis. Arq Bras Cardiol. 2017 Oct;109(4):357-367. doi: 10.5935/abc.20170125. Epub 2017 Sep 4.
- Background: PubMed 30741484Toussaint-Duyster LCC, van der Cammen-van Zijp MHM, de Jongste JC, Tibboel D, Wijnen RMH, Gischler SJ, van Rosmalen J, IJsselstijn H. Congenital diaphragmatic hernia and exercise capacity, a longitudinal evaluation. Pediatr Pulmonol. 2019 May;54(5):628-636. doi: 10.1002/ppul.24264. Epub 2019 Feb 11.
- Background: PubMed 19573666Gischler SJ, Mazer P, Duivenvoorden HJ, van Dijk M, Bax NM, Hazebroek FW, Tibboel D. Interdisciplinary structural follow-up of surgical newborns: a prospective evaluation. J Pediatr Surg. 2009 Jul;44(7):1382-9. doi: 10.1016/j.jpedsurg.2008.12.034.
- Background: PubMed 9764441Fredriksen PM, Ingjer F, Nystad W, Thaulow E. Aerobic endurance testing of children and adolescents--a comparison of two treadmill-protocols. Scand J Med Sci Sports. 1998 Aug;8(4):203-7. doi: 10.1111/j.1600-0838.1998.tb00193.x.
- Background: PubMed 7564970Bailey RC, Olson J, Pepper SL, Porszasz J, Barstow TJ, Cooper DM. The level and tempo of children's physical activities: an observational study. Med Sci Sports Exerc. 1995 Jul;27(7):1033-41. doi: 10.1249/00005768-199507000-00012.
- Background: PubMed 34192010Stockwell S, Trott M, Tully M, Shin J, Barnett Y, Butler L, McDermott D, Schuch F, Smith L. Changes in physical activity and sedentary behaviours from before to during the COVID-19 pandemic lockdown: a systematic review. BMJ Open Sport Exerc Med. 2021 Feb 1;7(1):e000960. doi: 10.1136/bmjsem-2020-000960. eCollection 2021.
- Individual participant dataSharing planned: No. We can share the raw MPST data when requested by other researchers.
Related trials for Development, Child
Recruiting
Strategies for Toddler ASD With Remote-therapy (STAR) Model for ASD
Autism Spectrum Disorder, Therapy
Recruiting
A Clinical Trial to Evaluate the Effects of a Children's Daily Multivitamin on Perceived Growth, Immune Health, Energy, and Focus in Children
Nutrient Gap in Children, Pediatric Health and Well-Being
Enrolling by invitationPhase 2
Extension Study of Infigratinib in Children With Achondroplasia (ACH)
Achondroplasia
Not yet recruiting
Leveraging Families to Promote Healthy Socio-Emotional Development in Children
Child Development, Parents
Recruiting
Smith Magenis Syndrome and Autism Spectrum Disorders
Smith-Magenis Syndrome, Autism Spectrum Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Marco Schnater, MD, PhD principal investigator
Erasmus Medical Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Muscle Power Sprint Test in people with Development, Child and Activity, Motor, run by Erasmus Medical Center at 1 site in Netherlands.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 25 Feb 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Louis Dossche, MD (0031107036084, l.dossche@erasmusmc.nl), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Reference values for the MPST for children aged 5-12 years, both male and female. (time frame: Data gathering: 6 months, data processing: 6 months.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06448520, which also lists 7 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Feb 2025.